BNET Industries
Allergan Inc. (AGN) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $3.9B
- Profit
- Dec 31 2007
- $499.3M
- Market Cap
- Nov 28 2008
- $11.5B
Latest News and Analysis
Commenting on the U.S. Food and Drug Administration Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX®, Rather Than BOTOX® Cosmetic for Aesthetic Use
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today commented on and provided support for the U.S. Food and Drug Administration's FDA "Early Communication" regarding a safety review of botulinum toxins in the United States.
Inspire Reports Fourth Quarter and Full Year 2006 Financial Results
2006 Revenue up 59% over 2005 DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the fourth quarter and year ended December 31, 2006, reporting a net loss of $15.5 million, or ($0.37) per share, for the fourth quarter, and a net loss of $42.1...
Allergan Announces FDA Issues Approvable Letter for COMBIGAN™ 0.2%/0.5%
IRVINE, Calif. -- Allergan Inc. (NYSE:AGN) today announced that the U.S. Food and Drug Administration FDA issued an approvable letter for COMBIGAN[TM] (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% for the reduction of elevated intraocular pressure IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due...
Allergan Announces FDA Approval of INAMED® Silicone-Filled Breast Implants for Breast Augmentation, Reconstruction and Revision Surgery
-- Women in the United States Now Have New Options in Breast Aesthetics --
Allergan Announces FDA Approval of Juvederm® Gel Family of Products for the Treatment of Facial Wrinkles and Folds; 'Next Generation' Smooth Gel, Non-Animal Dermal Fillers Offer Natural, Long-Lasting Results
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN), the makers of BOTOXR Cosmetic Botulinum Toxin Type A, today announced the U.S. Food and Drug Administration FDA's approval of the JuvedermR gel family of products, a 'next generation' of hyaluronic acid dermal fillers that provide a smooth, long-lasting correction of facial wrinkles and...
Allergan Receives Written Response from FDA on Oral Tazarotene
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that it has received a written response from the U.S. Food and Drug Administration FDA regarding Allergan's request for formal dispute resolution on its oral tazarotene capsule New Drug Application NDA. In the response, the FDA outlined multiple potential options for improving...
Artes Medical Appoints Adelbert L. Stagg, Ph.D. as VP, Regulatory Affairs and Quality Assurance; Former Allergan Regulatory Affairs Leader to Manage FDA Approval of Company Products
SAN DIEGO -- Artes Medical Inc., a privately-held specialty pharmaceutical and medical device company, today announced the hire of Adelbert L. Stagg, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance. Dr. Stagg, who was formerly part of the regulatory leadership at Allergan responsible for managing BOTOXR and BOTOXR Cosmetic...
Allergan Update Regarding Florida Facility Investigation; Company Urges Physicians to Use Only FDA-Approved and U.S. Licensed Botulinum Toxin Products to Protect Public Health
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) provided a further update today regarding the investigation into potentially unlicensed and unregulated practices at a facility in Fort Lauderdale, Florida that resulted in the hospitalization of four patients. News reports have surfaced that in a raid of the clinic, Advanced Integrated Medical Center,...
FDA denies approval for Allergan pill for psoriasis.
By Bernard J. Wolfson, The Orange County Register, Calif. Knight Ridder/Tribune Business News By Bernard J. Wolfson, The Orange County Register, Calif. Knight Ridder/Tribune Business News
Allergan Receives Approvable Letter for LUMIGAN — bimatoprost-timolol
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced that the U.S. Food and Drug Administration FDA has issued an approvable letter for its LUMIGANR timolol combination product for glaucoma (bimatoprost 0.03 percent/timolol 0.05 percent ophthalmic solution). An approvable letter sets out the conditions that a company must meet in order...
FDA Approves BOTOX — Botulinum Toxin Type A — for Treatment of Severe Underarm Sweating; New Approval Marks Fourth Therapeutic Indication for Allergan's BOTOX Over Last 15 Years
IRVINE, Calif. -- Allergan, Inc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration FDA approved BOTOXR botulinum toxin type A for the treatment of severe primary axillary hyperhidrosis severe underarm sweating that is inadequately managed with topical agents. Primary axillary hyperhidrosis often goes undiagnosed, misdiagnosed and untreated...
Allergan Announces Conference Call to Discuss FDA Advisory Committee Meeting on Oral Tazarotene
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) invites you to listen to Patricia S. Walker, M.D., Ph.D., Vice President, Clinical Research and Development, Skin Care Pharmaceuticals, Peter Kresel, Senior Vice President Global Regulatory Affairs, and Jim Hindman, Senior Vice President Treasury, Risk and Investor Relations, discuss the clinical aspects of the...
FDA Approves Allergan's Fourth Generation Ophthalmic Anti-Infective ZYMAR
Business Editors/Health/Medical Writers
Allergan 'dry-eye' drug gets FDA approval
Allergan, in late December, received FDA approval for Restasis (cyclosporine ophthalmic emulsion, 0.05%), the first and only therapy for patients with chronic dry eye disease, or CDED.
Allergan's RESTASIS Approved by the FDA; The First And Only Therapeutic Treatment To Increase Tear Production In Patients With Chronic Dry Eye Due To Ocular Inflammation
Business Editors & Health/Medical Writers
Allergan Receives Approval From the FDA for AVAGE to Treat Fine Facial Wrinkles; Provides a Complementary Treatment To BOTOX Cosmetic
Business Editors & Health/Medical Writers
FDA Accuses Allergan of Misleading Botox Advertisements.
By Bernard J. Wolfson, The Orange County Register, Calif. Knight Ridder/Tribune Business News By Bernard J. Wolfson, The Orange County Register, Calif. Knight Ridder/Tribune Business News
FDA approves Botox for cosmetic procedures
Baltimore cosmetic surgeons are anticipating one of their most popular procedures will generate even more revenue with yesterday's approval of Botox by the U.S. Food & Drug Administration. The drug, a purified strain of botulinum toxin, for years has been used cosmetically to reduce lines and wrinkles, though its...
Allergan's BOTOX COSMETIC Receives Approval by the FDA for the Treatment of Glabellar Lines -Brow Furrow-; New Cosmetic Indication Underscores Product's Versatility
Business Editors & Health/Medical Writers
Multimedia Available: Allergan's Botox Cosmetic Receives Approval by the FDA for the Treatment of Glabellar Lines-Brow Furrow
Business Editors
- Next »
- page 1 of 2
- « Previous
Sort byClose
View Related Content by Tag Close
- Incorporated: 1948
- CEO: Mr. David E.I. Pyott
Allergan is a health care company that develops and markets specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological and other specialty markets. Co. targets products and technologies related to specific disease areas such as glaucoma, retinal disease, dry eye, psoriasis, acne, movement disorders, neuropathic pain and genitourinary diseases. Co.'s products are sold to, among others, drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, hospitals and ambulatory surgery centers.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Allergan Inc. Company Info
Board of Directors
Mr. David E.I. Pyott
Chairman
Mr. Leonard D. Schaeffer
Mr. Robert A. Ingram
Mr. Rusell T. Ray
Mr. Gavin S. Herbert
Chairman Emeritus
Dr. Herbert W. Boyer Ph.D.
Vice-Chairman
Dr. Deborah Dunsire M.D.
Prof. Trevor M. Jones Ph.D.
Mr. Louis J. Lavigne Jr.
Ms. Dawn Hudson
Mr. Michael R. Gallagher
Dr. Stephen J. Ryan M.D.
Contact Information
2525 Dupont Drive
P.O. Box 19534
Irvine, CA
714 246-4500
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
